Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus

Kazuhiko Kido1*, Yasir Abdul Ghaffar2*, James C. Lee3, Christopher Bianco2, Mikiko Shimizu4, Tsuyoshi Shiga5, Masayuki Hashiguchi6

1 Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV, United States of America, 2 Division of Cardiology, Department of Medicine, West Virginia University, Morgantown, WV, United States of America, 3 Department of Pharmacy Practice, University of Illinois Chicago College of Pharmacy, Chicago, IL, United States of America, 4 Department of Pharmaceutics and Pharmacometrics, School of Pharmacy, Shujitsu University, Okayama, Japan, 5 Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, Tokyo, Japan, 6 Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy, Keio University, Tokyo, Japan

* These authors contributed equally to this work.

Abstract

Current American College of Cardiology/American Heart Association guidelines for stroke or ST-elevation myocardial infarction recommend the use of oral vitamin K antagonists (VKAs) as a first-line anticoagulant. Although several studies have compared the use of direct oral anticoagulants (DOACs) to VKAs for left ventricular thrombus (LVT) anticoagulation therapy, they are small scale and have produced conflicting results. Thus, this meta-analysis was performed to aggregate these studies to better compare the efficacy and safety of DOACs with VKAs in patients with LVT. Cochrane Library, Google Scholar, MEDLINE, and Web of Science database searches through January 10, 2021 were performed. Eight studies evaluating stroke or systemic embolism (SSE), six studies for LVT resolution, and five studies for bleeding were included. There were no statistically significant differences in SSE (OR 0.89; 95% CI 0.46, 1.71; p = 0.73; I² = 45%) and LVT resolution (OR 1.13; 95% CI 0.75, 1.71; p = 0.56; I² = 1%) between DOAC and VKA (reference group) therapy. DOAC use was significantly associated with lower bleeding event rates compared to VKA use (OR 0.61; 95% CI 0.40, 0.93; p = 0.02; I² = 0%). DOACs may be feasible alternatives to vitamin K antagonists for LV thrombus treatment. Randomized controlled trials directly comparing DOACs with VKAs are needed.

Introduction

Left ventricular thrombus (LVT) development is common in patients with severe left ventricular (LV) dysfunction, often in the setting of acute anterior wall myocardial infarction (MI) and nonischemic cardiomyopathies, and is associated with increased risk of stroke or systemic embolism (SSE) [1–3]. Patients with cardioembolic stroke are at highest risk of in-hospital
mortality during the acute phase, with subsequent long-term disability following the initial course [4,5]. Pre-requisites for LVT formation include endothelial injury, hypercoagulability, and venous stasis, (i.e., Virchow’s triad), and can occur as early as within 24 hours to 3 months following MI [1]. Additionally, the potential for LVT cerebral embolization persists in patients who develop chronic LV dysfunction. In heart failure with reduced ejection fraction (HFrEF), a hypercoagulable state is noted with increased incidence of LVT and higher risk of thromboembolism [6].

Current American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines recommend the use of oral vitamin K antagonists (VKAs) as the primary anticoagulant in the management of ST-elevation myocardial infarction and asymptomatic LV mural thrombi (Class IIa, Level of Evidence C) [7]. The European Society of Cardiology (ESC) more specifically recommends 6 months of oral anticoagulant therapy with VKA (Class IIa, Level of Evidence C) [8]. Achieving adequate anticoagulation with warfarin requires medication adherence, dietary consistency, frequent laboratory monitoring, and a narrow time in therapeutic range (TTR). These disadvantages have led to increased adoption of direct oral anticoagulants (DOACs) for anticoagulation treatment of thromboembolic diseases such as atrial fibrillation (AF) and venous thromboembolism (VTE) [9].

DOAC use for anticoagulation for LVT in patients with LV dysfunction and STEMI remains controversial. LVT formation is pathologically similar to left atrial appendage thrombus (LAAT) formation due to a low-flow and low-shear setting, with DOAC use for left atrial appendage thrombus (LAAT) appearing to be highly efficacious [10]. Correspondingly, the safety and efficacy of DOACs observed in the prevention of thromboembolism and stroke in atrial fibrillation have served as a basis for DOAC use for LVT anticoagulation [11–14]. Since the publication of ACC/AHA guidelines in 2013, multiple studies and case series have compared DOACs with VKAs in patients with LVT but have produced discordant results. Despite the suggestion of generally improved safety profile of DOACs over VKA in other anticoagulation contexts, the safety and efficacy of DOACs for LVT anticoagulation remain inconclusive due to inconsistent trial outcomes thus far [15]. Thus, this meta-analysis of published full-text clinical study manuscripts comparing DOACs to VKAs in LVT was performed to better compare the efficacy and safety of DOACs with VKAs in patients with LVT, specifically SSE, LVT resolution, and overall bleeding.

**Methods**

Literature search keywords utilized for the MEDLINE search included: ((left ventricular thrombus) or (left ventricular thrombi)) and ((direct oral anticoagulant) or apixaban or dabigatran or edoxaban or rivaroxaban)). No limit was used for database searches. Database searches through January 10, 2021 were performed using the Cochrane Library, Google Scholar, MEDLINE, and Web of Science. Two independent investigators (KK, MH) performed the literature search and selected articles based on pre-specified inclusion and exclusion criteria. Inclusion criteria included: 1. patient age >18 years old diagnosed with LVT and 2. clinical studies comparing DOACs with VKAs. Conference abstracts were excluded. Studies were excluded if they were case series, non-English articles, or studies not evaluating VKAs.

Two independent investigators (KK, JL) extracted baseline characteristics, SSE, LVT resolution, bleeding outcome results, follow-up period, and number of subjects. The primary efficacy outcome was SSE event rate, and the primary safety outcome was bleeding. The secondary efficacy outcome was LVT resolution rate. Major bleeding was not evaluated since this was not evaluated in the majority of included studies. Study quality was evaluated using the Newcastle-Ottawa Scale (NOS) [16].
A random-effects model was selected, and a fixed effects model was used for sensitivity analysis. Heterogeneity was assessed with $I^2$ statistics. Publication bias was assessed with the Egger regression test. An odds ratio (OR) and 95% confidence interval (CI) were estimated, and p-values $< 0.05$ were defined as statistically significant. The Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines were followed to conduct this meta-analysis [17]. All results were analyzed with RevMan 5.3 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen). The protocol was not registered.

**Results**

A total of 122 articles were evaluated for eligibility, and eight studies were included for the final analysis (Fig 1) [11–13,15,18–21]. One study was excluded because the comparison of VKA with DOACs was not the primary study purpose and less than 5 patients on DOACs were included [10].

Tables 1 and 2 describe the key baseline characteristics, follow-up period, and outcomes of the included studies. All included studies evaluated SSE, 6 studies evaluated LVT resolution, and 5 studies evaluated bleeding. NOS quality assessment results are included in Supporting Information (S1 Table). A total of 454 patients in the DOAC group and 1438 patients in the VKA group were evaluated.

There were no significant differences in SSE (OR 0.89; 95% CI 0.46, 1.71; p = 0.73; $I^2 = 45\%$) and LVT resolution (OR 1.13; 95% CI 0.75, 1.71; p = 0.56; $I^2 = 1\%$) between the DOAC and VKA (reference group) groups (Figs 2 and 3). DOACs were associated with significantly lower bleeding event rates compared to VKA (OR 0.61; 95% CI 0.40, 0.93; p = 0.02; $I^2 = 0\%$) (Fig 4). The fixed effects model found no significant difference in SSE (OR 0.61; 95% CI 0.40, 0.93; p = 0.02; $I^2 = 0\%$) and LVT resolution (OR 1.15; 95% CI 0.77, 1.73; p = 0.50), and DOAC was still associated with significantly lower bleeding event rates compared to VKAs (OR 0.60; 95% CI 0.39, 0.91; p = 0.02; $I^2 = 0\%$). No significant funnel plot asymmetry was found by the Egger regression test, indicating no significant publication bias (SSE: p = 0.67; LVT resolution: p = 0.75; bleeding: p = 0.91).

**Discussion**

This meta-analysis found DOAC use for the anticoagulation treatment of LVT had comparable SSE and LVT resolution rates to warfarin. Additionally, patients treated with DOACs experienced significantly lower bleeding events compared to warfarin. The SSE and LVT resolution outcomes of this meta-analysis are congruent with the outcomes of other recently published meta-analyses [22–27]. Unlike previous meta-analyses, however, this meta-analysis only included fully published manuscripts and did not include abstracts due to their preliminary nature, which likely reduced the chance of error for data extraction [22,24]. Especially, fully published data from the biggest included study by Bass et al. was included in our meta-analysis but other meta-analyses only included abstract data.

Notably and contrary to our findings, however, Robinson et al observed increased SSE rates with DOAC use compared to warfarin, although these events occurred late in the course of treatment when survival curves began to diverge [15]. Several plausible explanations exist. First, although treatment switching was allowed between the study groups, increased SSE risk persisted even after adjusting for several confounders in the multivariate analysis [15]. Second, this outcome may have been influenced by the DOAC studied. Apixaban was the predominant DOAC used (76.2% of participants), possibly due to insurance coverage or local and regional practice variations [28]. Third, the use of both reduced and standard apixaban doses (2.5 mg vs 5mg twice a day) and anticoagulation therapy interruption during acute hospitalizations...
and post discharge following LVT diagnosis may have led to the later emergence of strokes [29]. In response, Robinson et al reported only 4 of 73 (5%) patients treated with apixaban were treated with the low-dose regimen and none developed stroke and that all anticoagulation interruptions were accounted for in the time dependent analysis. Despite these adjustments, DOAC use remained a predictor of SSE [30].

With respect to LVT resolution, a recent large meta-analysis of patients taking DOACs observed thrombus resolution in only 80% of patients [31]. Patients anticoagulated for LVT may remain at increased risk of thromboembolism and continued presence of unresolved left
ventricular thrombi despite complete initial thrombus resolution [32]. Previous data have also suggested a persistent risk of thromboembolism despite LVT resolution, with one platelet imaging study demonstrating externally detectable ongoing platelet accumulation indicating continued surface activity [33]. At this time, it remains unclear if duration of anticoagulation therapy should extend beyond 3 months and which DOAC dose is the most appropriate for use of a DOAC plus P2Y12 inhibitor two-drug regimen was associated with lower bleeding compared with VKA and P2Y12 inhibitor [35]. Despite enrolling a large number of patients on triple antithrombotic therapy (68.3% DOAC vs 70.0% VKA), Jones et al found less major bleeding with DOAC use compared to VKA (0% vs 6.7%, p = 0.030) [18]. Bass et al, on the other hand, observed comparable bleeding events (10.9% vs 7.8%, p = 0.40) between warfarin and DOAC therapy, although more warfarin patients received blood products compared to those taking a DOAC (25.8% vs 13.9%, p < 0.001) [11].

Formation of an LV thrombi mirrors that of LAAT and occurs in a low-flow and low-shear environment. This contrasts with thrombus formation with mechanical heart valves, which is

| Study          | Age (years, mean ± SD or [IQR]) | Sex (% male) | SCR (mg/dL) or eGFR (mL/min/1.73m²) | LVEF (% ± SD or [IQR]) | ICM (%) or MI % | HTN (%) | DM (%) | HLD (%) | AF (%) | Antipla
t

| Daher et al. DOAC vs. VKA 57±14 vs. 61±13 | 82.4 vs. 83.0 | NR | 54.1±8 vs. 56.1±12 | ICM 88 vs. 74 | 59 vs. 40.5 | 12 vs. 21.4 | 29.4 vs. 43 | NR | NR |

| Robinson et al. DOAC vs. warfarin 58.1±14.9 vs. 58.2±15.1 | 77.7 vs. 72 | eGFR 80.5±29.3 vs. 75.8±29.8 | 27.2±13.8 vs. 28.2±12.4 | ICM 54.5 vs. 62.7 | 71.1 vs. 75 | 29.8 vs. 39 | 58.7 vs. 53.4 | 24.8 vs. 19.1 | 63.6 vs. 69.5 |

| Ali et al. DOAC vs. Warfarin 58.2±1.9 vs. 58.1±1.6 | 81.3 vs. 81.7 | NR | 23±9.4 vs. 23.2±11.2 | Overall: ICM 58% Acute MI 15% | NR | 37.5 vs. 30 | NR | 28.1 vs. 30 | Overall: ASA 65.45; CLOP 14.5; TIC 0.91; PRAS 1.82 |

| Guddeti et al. DOAC vs Warfarin 60.7±13.1 vs. 61.3±12.2 | 79.0 vs. 68.8 | NR | 25 [20–40] vs. 25 [25–35] | ICM 52.6 vs. 60 MI 52.6 vs. 56.4 | 79.0 vs. 76.3 | 15.8 vs. 43.0 | NR | 21.1 vs. 22.5 | ASA 57.9 vs. 67.5; P2Y12i: 15.8 vs. 15 |

| Iqbal et al. DOAC vs VKA 62±13 vs. 62±14 | 91 vs. 89 | 1.13±0.23 vs. 1.03±0.35 | 31±13 vs. 35±13 | ICM 82 vs. 89 | 41 vs. 29 | 86 vs. 31 | 18 vs. 15 | 14 vs. 5 | ASA 41 vs. 65; CLOP 50 vs. 35; TIC 0 vs. 10 |

| Willeford et al. DOAC vs. Warfarin 54 [48–64] vs. 56 [49–65.5] | 77.4 vs. 80.6 | NR | NR | MI 22.7 vs. 26.4 | 41.9 vs. 36.4 | 18.2 vs. 28.7 | NR | 13.6 vs. 18.6 | ASA 22.7 vs. 54.3; P2Y12i: 13.6 vs. 27.9 |

| Jones et al. DOAC vs. Warfarin 58.73±14.2 vs. 60.81±14.3 | 80.4 vs. 85 | eGFR 68.24±15.8 vs. 66.11±18.8 | 33.5±10.0 vs. 35.4±9.0 | Prior MI 5±5 vs. 36.7 | 60.5 vs. 36.4 | 18.4 vs. 16.7 | 50 vs 31.7 | NR | Single antiplatelet: 24.4 vs 21.7; Triple therapy 68.3 vs 70.0 |

| Bass et al. DOAC vs warfarin 63.4±16.7 vs 61.6±15.3 | 69.4 vs. 70.9 | SCR 1.00 ± 0.38 ± 1.33 ± 1.12 | NR | MI 42.8 vs. 57.6 | NR | NR | NR | 61.7 vs. 45.8 | 46.7 vs. 55.7 |

AF: Atrial fibrillation; ASA: Aspirin; CLOP: Clopidogrel; DOAC: Direct oral anticoagulant; DM: Diabetes, eGFR: Estimated glomerular filtration rate; HTN: Hypertension; HLD: Hyperlipidemia; ICM: Ischemic cardiomyopathy; IQR: Interquartile range; LV: Left ventricular; LVEF: Left ventricular ejection fraction; MI: Myocardial infarction; NR: Not reported; P2Y12i: P2Y12 inhibitor; TIC: Ticagrelor; VKA: Vitamin K antagonist.

* The patient population of this study were patients presenting with acute MI undergoing primary percutaneous coronary intervention.

https://doi.org/10.1371/journal.pone.0252549.1001
predominantly contact-pathway mediated and where DOAC use has appeared to be inferior to warfarin [36]. When considering the similarities in thrombus formation and the efficacy of DOAC use in atrial fibrillation treatment, however, it is reasonable to conject similar efficacy.

### Table 2. Key study design characteristics and results of included studies.

| Study design                                  | Subjects (# patients, unless otherwise stated) | Follow-up period [IQR] | Efficacy outcome (DOAC vs. VKA) | Safety outcome (DOAC vs. VKA) |
|-----------------------------------------------|------------------------------------------------|------------------------|---------------------------------|-------------------------------|
| Daher et al. Single-center retrospective cohort study | DOAC 17 (API 12, RIV 4, DAB 1) vs. VKA 42 | NR                     | SSE: 11.8% vs. 9.5% LV thrombus resolution at 3 months: 70.6 vs. 71.5% | NR                            |
| Robinson et al. Multi-center retrospective cohort study | DOAC 121 (API > RIV > DAB) vs. warfarin 236 | Median 351 days [51–866] | SSE at 1 month: 14.0% vs. 5.9% (p = 0.01) | Bleeding: 6.6% vs. 8.1% |
| Ali et al. Single-center retrospective cohort study | DOAC 32 (API 13; RIV 18; DAB 1) vs. warfarin 60 | <1 year: 24.6% 1–3 years: 22.7% 3–5 years: 17.3% >5 years: 18.2% | SSE: 6% vs 26.6% LV thrombus resolution: 53% vs. 62% | Bleeding: 0 vs. 3.3% (hemorrhagic CVA) |
| Guddeti et al. Multi-center retrospective cohort study | DOAC 19 (API 15; RIV 2; DAB 2) vs. warfarin 80 | Mean 10.4±3.4 months Median 1 year | Ischemic stroke at 1 year: 0 vs. 2.5% LV thrombus resolution: 80% vs. 81% | Bleeding: 5.3% vs 6.25% |
| Iqbal et al. Single-center retrospective cohort study | DOAC 22 (API 8; RIV 13; DAB 1) vs. warfarin 62 | Mean 3.0±1.4 years | Thromboembolic events: 0 vs. 2% LV thrombus resolution: 65% vs 76% All-cause mortality: 14% vs. 10% Repeat hospitalization: 45% vs. 50% | Clinically relevant bleeding: 0 vs. 10% |
| Willeford et al. Single-center retrospective cohort study | DOAC 22 (API 4; RIV 18) vs. warfarin 129 | Median 254 days [98–343] | Composite of LV thrombus persistence and SSE: 40.9% vs. 54.3% | Composite of hemorrhagic stroke or bleeding requiring transfusion: 4.5% vs. 3.9% |
| Jones et al. Single-center retrospective cohort study | DOAC 41 (API 36.5%, RIV 58.5%, EDO 5%) vs. warfarin 60 | Median 2.2 years | LV thrombus resolution at 1 year: 82% vs. 64.4% (p = 0.0018) SSE: 2.4% vs. 5% | Bleeding BARC >2: 0% vs. 6.7% |
| Bass et al. Multi-center retrospective cohort study | DOAC 180 (API 79, RIV 77, DAB 29) vs. warfarin 769 | NR | Thromboembolic stroke at 90 days: 7.8% vs. 11.7% SSE: 33% vs. 30.6% | GUSTO bleeding 10.9% vs. 7.8% Blood product administration: 25.8% vs. 13.9% (p<0.001) |

API: Apixaban; DAB: Dabigatran; DOAC: Direct oral anticoagulant; EDO: Edoxaban; GUSTO: Global Use of Strategies to Open Coronary Arteries; IQR: Interquartile range; LV: Left ventricular; NOS: Newcastle-Ottawa scale; NR: Not reported; RIV: Rivaroxaban; SSE: Stroke or systemic embolism; VKA: Vitamin K antagonist.

https://doi.org/10.1371/journal.pone.0252549.t002

Fig 2. Forest plot of stroke of systemic embolism event rate in patients with left ventricular thrombus receiving DOACs versus VKA.

https://doi.org/10.1371/journal.pone.0252549.g002
when used in the treatment of LV thrombi. Additionally, DOACs may achieve more consistent anticoagulant effects and up to 50% reduced risk of intracranial hemorrhage compared to VKAs [37]. The favorable pharmacologic and clinical profile of DOACs will undoubtedly make their selection over warfarin for anticoagulation therapy attractive in patients with known or suspected LV thrombus.

**Limitations**

First, despite the large number of patients analyzed in this study, the overall number of outcome events was relatively modest, yielding wide CIs and increasing the risk of type II error. Second, the studies included were all observational studies, and consequently, endpoint ascertainment and classification were likely to vary according to each study’s definition. Third, this analysis did not have enough sample size to investigate the efficacy and safety of an individual DOAC compared to warfarin. Finally, DOAC dose and the duration of treatment for LV thrombus were not investigated in this study.

**Conclusions**

In this meta-analysis of published observational LVT anticoagulation full-text study data, there were no differences in stroke or systemic embolism and left ventricular thrombus resolution between direct oral anticoagulant and warfarin therapy. DOAC use was associated with significantly less bleeding compared to warfarin. Prospective, randomized clinical trials are needed.
to confirm the safety and efficacy of DOACs for the use of left ventricular thrombus anticoagulation.

**Supporting information**

S1 Checklist. PRISMA 2009 checklist Kido. (DOC)

S1 Table. Newcastle-Ottawa quality assessment of the included studies. (DOCX)

S1 Dataset. Dataset LV thrombus DOAC vs. Warfarin. (XLSX)

**Author Contributions**

**Conceptualization:** Kazuhiko Kido, Tsuyoshi Shiga.

**Investigation:** Kazuhiko Kido, James C. Lee, Masayuki Hashiguchi.

**Methodology:** Kazuhiko Kido, Mikiko Shimizu.

**Software:** Mikiko Shimizu, Masayuki Hashiguchi.

**Supervision:** Christopher Bianco, Tsuyoshi Shiga, Masayuki Hashiguchi.

**Writing – original draft:** Kazuhiko Kido, Yasir Abdul Ghaffar, James C. Lee, Christopher Bianco, Mikiko Shimizu, Tsuyoshi Shiga, Masayuki Hashiguchi.

**Writing – review & editing:** Kazuhiko Kido, Yasir Abdul Ghaffar, James C. Lee, Christopher Bianco, Mikiko Shimizu, Tsuyoshi Shiga, Masayuki Hashiguchi.

**References**

1. Delewi R, Zijlstra F, Piekk JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart 2012; 98:1743–9. https://doi.org/10.1136/heartjnl-2012-301962 PMID: 23151669

2. Visser CA, Kan G, Meltzer RS, Lie KI, Durrer D. Long-term follow-up of left ventricular thrombus after acute myocardial infarction. A two-dimensional echocardiographic study in 96 patients. Chest 1984; 86:532–6. https://doi.org/10.1378/chest.86.4.532 PMID: 6478891

3. Albaeni A, Chatilla K, Beydoun HA, Beydoun MA, Morsy M, Khalife WI. In-hospital left ventricular thrombus following ST-elevation myocardial infarction. Int J Cardiol 2020; 299:1–6. https://doi.org/10.1016/j.ijcard.2019.07.070 PMID: 31371119

4. Arboix A, Alló J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev 2010; 6:150–61. https://doi.org/10.2174/157340310791658730 PMID: 21804774

5. Murtagh B, Smalling RW. Cardiomebolic stroke. Curr Atheroscler Rep 2006; 8:310–6. https://doi.org/10.1007/s11883-006-0009-9 PMID: 16822397

6. Lip GY, Gibbons CR. Does heart failure confer a hypercoagulable state? Virchow’s triad revisited. J Am Coll Cardiol 1999; 33:1424–6. https://doi.org/10.1016/s0735-1097(99)00033-9 PMID: 10193748

7. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr., Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61:e78–e140. https://doi.org/10.1016/j.jacc.2012.11.019 PMID: 23256914

8. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39:119–77. https://doi.org/10.1093/eurheartj/ehx393 PMID: 29886621

9. Keita I, Aubin-Augier I, Lalanne C, Aubert JP, Chassany O, Duracinsky M, et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-
course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence 2017; 11:1625–34. https://doi.org/10.2147/PPA.S131157 PMID: 29026288

10. McCarthy CP, Murphy S, Venkateswaran RV, Singh A, Chang LL, Joice MG, et al. Left Ventricular Thrombus: Contemporary Etiologies, Treatment Strategies, and Outcomes. J Am Coll Cardiol 2019; 73:2007–9. https://doi.org/10.1016/j.jacc.2019.01.031 PMID: 30846340

11. Bass ME, Kiser TH, Page RL, McIlvennan CK, Allen LA, Wright G, et al. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis 2021. https://doi.org/10.1007/s11239-020-02371-6 PMID: 33408989

12. Daher J, Da Costa A, Hilaire C, Ferreira T, Pierrard R, Guichard JB, et al. Management of Left Ventricular Thrombus with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists. Clin Drug Investig 2020; 40:343–53. https://doi.org/10.1007/s40261-020-00898-3 PMID: 32144651

13. Guddeti RR, Anwar M, Walters RW, Apala D, Pajuuru V, Kousa O, et al. Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational Study. Am J Med 2020; 133:1488–91. https://doi.org/10.1016/j.amjmed.2020.05.025 PMID: 32598904

14. Alizadeh M, Antoniou S, Fhadil S, Rathod KS, Guttmann O, Knight C, et al. P6426The use of direct oral anti-coagulations (DOACs) compared to vitamin K antagonist in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J 2019; 40.

15. Robinson AA, Trankle CR, Eubanks G, Schumann C, Thompson P, Wallace RL, et al. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA cardiology 2020. https://doi.org/10.1001/jamacardio.2020.0662 PMID: 32320043

16. Newcastle-Ottawa Scale. at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

17. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Med 2009; 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097 PMID: 19621072

18. Jones DA, Wright P, Alizadeh MA, Fhadil S, Rathod KS, Guttmann O, et al. The Use of Novel Oral Anti-Coagulant’s (NOAC) compared to Vitamin K Antagonists (Warfarin) in patients with Left Ventricular thrombus after Acute Myocardial Infarction (AMI). Eur Heart J Cardiovascular Pharmacother 2020. https://doi.org/10.1093/ehjcvp/pva096 PMID: 32730627

19. Iqbal H, Straw S, Craven TP, Stirling K, Wheatcroft SB, Witte KK. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail 2020. https://doi.org/10.1002/ehf2.12718 PMID: 32583975

20. Willeford A, Zhu W, Stevens C, Thomas IC. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus. Ann Pharmacother 2020; 1060028020975111. https://doi.org/10.1177/1060028020975111 PMID: 33191781

21. Ali Z, Ison N, Dalia T, Sami F, Mahmood U, Shah Z, Gupta K. Direct oral anticoagulant use in left ventricular thrombus. Thromb J 2020; 18:29. https://doi.org/10.1186/s12959-020-00242-x PMID: 33132763

22. Dalia T, Lahan S, Ranka S, Goyal A, Zoubek S, Gupta K, et al. Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis. Thromb J 2021; 19:7. https://doi.org/10.1186/s12959-021-00259-w PMID: 33517885

23. Trongtorsk A, Thangjui S, Kewcharoen J, Polpichai N, Yodsuwan R, Kittipibul V, et al. Direct oral anticoagulants vs. vitamin K antagonists for left ventricular thrombosis: a systematic review and meta-analysis. Acta Cardiol 2021:1–10. https://doi.org/10.1002/ehjcvp/pvaa096 PMID: 33393861

24. Gue YX, Spathakis N, Gorog DA, Farag M. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis. Am J Cardiol 2021. https://doi.org/10.1016/j.amjcard.2020.12.014 PMID: 33599200

25. Saleiro C, Lopes J, De Campos D, Puga L, Costa M, Gonçalves L, et al. Left Ventricular Thrombus Therapy With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review and Meta-Analysis. J Cardiovasc Pharmacol Ther 2020:1074248420977567. https://doi.org/10.1177/1074248420977567 PMID: 33259235

26. Camilli M, Lombardi M, Del Buono MG, Chiabrando JG, Vergallo R, Niccoli G, et al. Direct Oral Anticoagulants versus Vitamin K Antagonists for the treatment of Left Ventricular Thrombosis: a systematic review of the literature and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2020.

27. Al-Abcha A, Herzallah K, Saleh Y, Mujer M, Abdelkarim O, Abdelnabi M, et al. The Role of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi: A Meta-Analysis and Systematic Review. Am J Cardiovasc Drugs 2020. https://doi.org/10.1007/s40266-020-00458-2 PMID: 33354748
28. Sedhom R, Abdelmaseeh P, Megaly M, Asinger R. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review. Am J Med 2020; 133:1266–73.e6. https://doi.org/10.1016/j.amjmed.2020.05.012 PMID: 32565258

29. Manmadhan A, Berger JS, Ahuja T. To DOAC or Not to DOAC for Left Ventricular Thrombi-What Is the Dose? JAMA cardiol 2021.

30. Robinson AA, Trankle CR, Eubanks G. To DOAC or Not to DOAC for Left Ventricular Thrombi-What Is the Dose?-Reply. JAMA cardiol 2021. https://doi.org/10.1001/jamacardio.2020.6897 PMID: 33471031

31. Kajy M, Shokr M, Ramappa P. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: Systematic Review of Current Literature. Am J Ther 2019.

32. Navar AM, Mehran R. High Rates of Off-label Prescribing and the Urgent Need for a Randomized Clinical Trial. JAMA cardiol 2020. https://doi.org/10.1001/jamacardio.2020.0612 PMID: 32319997

33. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90:61–8. https://doi.org/10.1161/01.cir.90.1.61 PMID: 8026047

34. van Rein N, Heide-Jørgensen U, Liljereng WM, Dekkers OM, Sørensen HT, Cannegie ter SC. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation 2019; 139:775–86. https://doi.org/10.1161/CIRCULATIONAHA.118.036248 PMID: 30586754

35. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med 2019; 380:1509–24. https://doi.org/10.1056/NEJMoa1817083 PMID: 30883055

36. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369:1206–14. https://doi.org/10.1056/NEJMoa1300615 PMID: 23991661

37. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep 2014; 16:480. https://doi.org/10.1007/s11886-014-0480-9 PMID: 24643903